PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

sulindac Side Effects

The reactions most often reported to the FDA for sulindac (also sold as Clinoril), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

2,380
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of sulindac come from 2,380 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 2,380 reports to the FDA Adverse Event Reporting System (FAERS) for sulindac (Clinoril): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

2,380

Reports Mentioning Death

132

5.5% of reports — not proof the medicine caused the death

Hospitalizations

620

26.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PAIN
182
FATIGUE
151
ARTHRALGIA
138
NAUSEA
123
PAIN IN EXTREMITY
114
ASTHENIA
106
DIARRHOEA
102
HEADACHE
98
BACK PAIN
95
DYSPNOEA
95
DRUG HYPERSENSITIVITY
92
DIZZINESS
84
PRURITUS
82
FALL
80
CHRONIC KIDNEY DISEASE
78
PNEUMONIA
77
MALAISE
73
RASH
72
RENAL FAILURE
67

Who Reports Side Effects

Gender Distribution

Female 1,581 (70%)
Male 684 (30%)
Unknown 5

Age Distribution

0-17 29 (2%)
18-44 224 (14%)
45-64 746 (48%)
65-74 357 (23%)
75+ 194 (13%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 132 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 39
CARDIAC ARREST 12
TOXICITY TO VARIOUS AGENTS 11
SEPSIS 9
PULMONARY EMBOLISM 8
RENAL FAILURE 8
ACUTE KIDNEY INJURY 7
CARDIO-RESPIRATORY ARREST 7
CHRONIC KIDNEY DISEASE 7
DRUG INTERACTION 6
HEPATIC CIRRHOSIS 6
RENAL IMPAIRMENT 6
RESPIRATORY ARREST 6
COMPLETED SUICIDE 5
PANCYTOPENIA 5
RESPIRATORY FAILURE 5
CARDIAC FAILURE CONGESTIVE 4
END STAGE RENAL DISEASE 4
HAEMATEMESIS 4
LOSS OF CONSCIOUSNESS 4

Reactions in Hospitalization Reports

Top reactions in 620 reports where hospitalization was an outcome.

Reaction Reports
FALL 47
PAIN 47
FATIGUE 45
ASTHENIA 42
NAUSEA 38
DIARRHOEA 37
DYSPNOEA 37
ARTHRALGIA 36
PNEUMONIA 36
DIZZINESS 34
BACK PAIN 33
VOMITING 33
CONSTIPATION 29
ABDOMINAL PAIN 28
PAIN IN EXTREMITY 28
WEIGHT DECREASED 28
ACUTE KIDNEY INJURY 27
RENAL FAILURE 27
DEPRESSION 25

Compare sulindac vs abatacept →

What the FAERS Data Reveals About sulindac Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 2,380 voluntary reports linked to sulindac and its brand equivalents (Clinoril), spanning 2004 through 2025. Of those, 132 (5.5%) listed death as an outcome and 620 (26.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 70% were female and 30% male; age distribution skews toward 45-64, with 746 reports in that bracket. The single most reported reaction is pain with 182 submissions, followed by fatigue and arthralgia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.